<DOC>
	<DOCNO>NCT01583608</DOCNO>
	<brief_summary>The registry aim evaluate safety , performance efficacy Everolimus-eluting bioresorbable vascular scaffold ( BVS ) system patient de novo native coronary artery lesion all-day clinical practice .</brief_summary>
	<brief_title>ABSORB : Postmarketing Surveillance Registry Monitor Everolimus-eluting Bioresorbable Vascular Scaffold Patients With Coronary Artery Disease</brief_title>
	<detailed_description>Bioresorbable scaffold transient implant . They act like drug-eluting metallic stent ( DES ) first 3 month support vessel wall thereby keep artery patent . Subsequently , resorption scaffold begin structure loosens . As result everolimus release , neointimal growth inhibit similar DES . Finally implant reabsorb completely 2-3 year . BVS term late stent thrombosis may safer DES . Transiently scaffold vessel may regain natural curvature angulation well response nitroglycerine endothelial function .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>The recommendation implant BVS individual patient purely base clinical ground . These determine instruction use ( IFU ) BVS clinical experience accumulate far clinical studies.These study suggest BVS implant certain condition , determine patient coronary lesion treat : Eligible : Regarding patient Patient ≥ 18 ≤ 75 year live expectancy least 5 year ischemic heart disease ( chronic , NSTEMI unstable angina ) due one de novo native coronary artery lesion Patients evidence myocardial ischemia Regarding lesion Reference vessel diameter ≥ 2.0 mm ≤ 3.8 mm , visually estimate online QCA Percent diameter stenosis ≥ 50 % &lt; 100 % , visually estimate online QCA TIMI ≥1 Previous intervention target vessel lesion do ≥ 6 month prior index procedure &gt; 10 mm distal target lesion Previous intervention nontarget vessel lesion do ≥ 30 day prior index procedure In case &gt; 1 target lesion , different epicardial vessel Not eligible : Regarding patient Patient antiplatelet therapy and/or anticoagulant therapy contraindicate Patient know hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel , ticlopidine , prasugrel ticagrelor , everolimus , poly ( Llactide ) , poly ( D , Llactide ) , platinum , contrast sensitivity , adequately premedicated Patient know diagnosis acute myocardial infarction ( STEMI ) within 72 hour precede index procedure CK CKMB return within normal limit time procedure Patient currently experience clinical symptom consistent STEMI Patient current unstable arrhythmias Patient known leave ventricular ejection fraction &lt; 30 % Patient receive heart transplant organ transplant wait organ transplant Patient receiving schedule receive chemotherapy malignancy within 30 day prior procedure Patient receive immunosuppression therapy know immunosuppressive autoimmune disease Patient receiving schedule receive chronic anticoagulation therapy Elective surgery plan within first 6 month procedure require discontinue either aspirin clopidogrel Patient platelet count &lt; 100 000 cells/mm3 &gt; 700 000 cells/mm3 , WBC &lt; 3000 cells/mm3 , document suspect liver disease Patient know renal insufficiency Patient history bleed diathesis coagulopathy refuse blood transfusion Patient cerebrovascular accident transient ischemic neurological attack within past six month Patient significant GI urinary bleed within past six month Patient extensive peripheral vascular disease precludes safe 6 French sheath insertion Patient medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause non.compliance clinical study plan , confound data interpretation associate limited life expectancy ( i.e. , les one year ) Women childbearing potential undergone surgical sterilization postmenopausal Regarding lesion Aortoostial location Left main location Located within 2 mm origin LAD LCX Located within arterial saphenous vein graft distal diseased ( defined vessel irregularity per angiogram &gt; 20 % stenosed lesion visual estimation ) arterial saphenous vein graft Lesion involve bifurcation side branch vessel ≥ 2 mm diameter , ostial lesion &gt; 40 % stenosed visual estimation side branch require predilation Total occlusion ( TIMI flow 0 ) , prior wire pass Excessive tortuosity proximal within lesion ( extreme angulation ( ≥ 90° ) proximal within lesion ) Heavy calcification Restenotic previous intervention Target vessel contain thrombus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Drug elute stent</keyword>
	<keyword>Bioabsorbable</keyword>
	<keyword>Bioresorbable</keyword>
	<keyword>Coronary Stent</keyword>
	<keyword>Scaffold</keyword>
	<keyword>Stents</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Stentthrombosis</keyword>
</DOC>